Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Equity Average: 2017-2025

Historic Equity Average for Protagonist Therapeutics (PTGX) over the last 9 years, with Sep 2025 value amounting to $656.7 million.

  • Protagonist Therapeutics' Equity Average rose 22.38% to $656.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $656.7 million, marking a year-over-year increase of 22.38%. This contributed to the annual value of $506.0 million for FY2024, which is 83.23% up from last year.
  • As of Q3 2025, Protagonist Therapeutics' Equity Average stood at $656.7 million, which was down 3.21% from $678.5 million recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Equity Average high stood at $682.2 million for Q1 2025, and its period low was $215.9 million during Q1 2023.
  • Moreover, its 3-year median value for Equity Average was $536.6 million (2024), whereas its average is $476.9 million.
  • As far as peak fluctuations go, Protagonist Therapeutics' Equity Average soared by 277.86% in 2021, and later dropped by 28.25% in 2023.
  • Protagonist Therapeutics' Equity Average (Quarterly) stood at $314.8 million in 2021, then dropped by 27.07% to $229.6 million in 2022, then skyrocketed by 39.11% to $319.4 million in 2023, then skyrocketed by 88.97% to $603.6 million in 2024, then grew by 22.38% to $656.7 million in 2025.
  • Its Equity Average stands at $656.7 million for Q3 2025, versus $678.5 million for Q2 2025 and $682.2 million for Q1 2025.